Logo Image

Joseph Khabbaza, MD

Articles by Joseph Khabbaza, MD

The Role of Type 2 Inflammation of COPD

ByJoseph Khabbaza, MD ,Diego J. Maselli Caceres, MD ,MeiLan K. Han, MD, MS,Nicola Hanania, MD, MS

Panelists discuss the emerging recognition of type 2 inflammation in a subset of patients with chronic obstructive pulmonary disease (COPD) , highlighting differences from asthma in eosinophil thresholds and therapeutic responses, the roles of key cytokines IL-4, IL-13, and IL-5 in driving airway inflammation and remodeling, and the promise and challenges of targeting these pathways with biologics to improve outcomes while emphasizing the need for further research to understand the distinct inflammatory mechanisms in COPD.

Variabilities in Blood Eosinophils and Challenges in Interpretation in COPD

ByJoseph Khabbaza, MD ,Diego J. Maselli Caceres, MD ,MeiLan K. Han, MD, MS,Nicola Hanania, MD, MS

Panelists discuss the variability of blood eosinophil counts in chronic obstructive pulmonary disease (COPD), emphasizing the impact of factors such as corticosteroid use, infections, comorbidities, and smoking on their interpretation, and highlight the importance of considering these influences and monitoring trends over time to guide personalized treatment decisions effectively.

Implementation of Blood Eosinophil Testing Into Clinical Practice

ByJoseph Khabbaza, MD ,Diego J. Maselli Caceres, MD ,MeiLan K. Han, MD, MS,Nicola Hanania, MD, MS

Panelists highlight that while blood eosinophil counts are valuable for guiding chronic obstructive pulmonary disease (COPD) treatment, real-world challenges like fluctuating levels, incomplete symptom tracking, and fragmented care hinder their consistent use, underscoring the need for better data integration and clinician education.

The Utility of Blood Eosinophils and Other Emerging Biomarkers in COPD Management

ByJoseph Khabbaza, MD ,Diego J. Maselli Caceres, MD ,MeiLan K. Han, MD, MS,Nicola Hanania, MD, MS

Panelists discuss the growing role of blood eosinophils as a key biomarker in chronic obstructive pulmonary disease (COPD) management, highlighting their utility in guiding inhaled corticosteroid and biologic therapy decisions, the benefits of tracking longitudinal trends to improve accuracy, and the potential for integrating emerging biomarkers like FeNO to further personalize treatment despite current limitations.

Research Needs and the Future of COPD Treatment

ByJoseph Khabbaza, MD ,Diego J. Maselli Caceres, MD ,MeiLan K. Han, MD, MS,Nicola Hanania, MD, MS

Panelists discuss the future of chronic obstructive pulmonary disease (COPD) management, emphasizing the need for long-term data on newly approved therapies, the development of refined biomarkers like FeNO and imaging tools to guide precision treatment, and the potential for earlier intervention with biologics—all aimed at advancing personalized care and altering the disease trajectory in high-risk patients.

Managing Moderate to Severe COPD: Integrating New Therapies Into Practice

ByJoseph Khabbaza, MD ,Diego J. Maselli Caceres, MD ,MeiLan K. Han, MD, MS,Nicola Hanania, MD, MS

Panelists discuss the evolving role of newly approved chronic obstructive pulmonary disease (COPD) therapies—such as ensifentrine, mepolizumab, and dupilumab—in addressing persistent symptoms and frequent exacerbations despite standard care, highlighting their targeted use based on patient profiles, the practical challenges of integration into clinical practice, and the importance of education, shared decision-making, and personalized care to optimize outcomes in moderate to severe COPD.

New Horizons in COPD: Recent Approvals and GOLD Guideline Updates

ByJoseph Khabbaza, MD ,Diego J. Maselli Caceres, MD ,MeiLan K. Han, MD, MS,Nicola Hanania, MD, MS

Panelists discuss the impact of newly approved therapies for chronic obstructive pulmonary disease (COPD)—such as ensifentrine, mepolizumab, and dupilumab—highlighting their diverse mechanisms and potential to personalize treatment for patients with persistent symptoms or type 2 inflammation, while emphasizing the importance of guideline integration, clinician education, and collaboration across care teams to ensure timely and effective adoption in clinical practice.